Press Releases

Date Title and Summary Additional Formats
Toggle Summary Argos Therapeutics Opens Registration for Upcoming Investor Day
Event to be held on Wednesday, December 7, 2016 at NASDAQ MarketSite in New York City from 8:00-11:00 a.m. Eastern Time
View HTML
Toggle Summary Argos Therapeutics to Participate in 2016 EORTC-AACR-NCI Symposium
Company to review poster entitled "Development of an RNA loaded Dendritic Cell (DC) immunotherapy starting from tissue obtained via needle biopsy"
View HTML
Toggle Summary Cellthera Presents Preclinical Data at SITC Using Argos' Individualized Immunotherapy
- Demonstrates functional activity of AGS-003-like therapy in kidney cancer murine model, including in combination with sunitinib and PD-1 checkpoint inhibitor -
View HTML
Toggle Summary Argos Therapeutics Participating in Strategies for an HIV Cure 2016 Meeting
DURHAM, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® technology platform, today announced that the company is presenting
View HTML
Toggle Summary Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
- Dr. Richard D. Katz Joined as Chief Financial Officer - - Raised Gross Proceeds of $50 million in Follow-on Offering - - First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in HIV - - Investor Day Scheduled for December 7, 2016 - - Third Quarter Results Conference Call and
View HTML
Toggle Summary Argos Therapeutics to Participate in Upcoming Investor Conferences
DURHAM, N.C., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be
View HTML
Toggle Summary Argos Therapeutics to Participate in SITC 2016 Annual Meeting
DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® technology platform, today announced that the company will be
View HTML
Toggle Summary Argos Therapeutics to Host Third Quarter 2016 Financial Results Conference Call on Monday, November 14, 2016
DURHAM, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's third quarter
View HTML
Toggle Summary Argos Therapeutics Announces Publication of a Case Report on Long-term Survival of Kidney Cancer Patients Treated with AGS-003 Individualized Immunotherapy Featured in the Kidney Cancer Journal
Two advanced kidney cancer patients from a Phase 2 clinical trial maintain ongoing control of metastatic disease seven years after initiation of treatment with AGS-003 in combination with sunitinib. DURHAM, N.C., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc.
View HTML
Toggle Summary Argos Therapeutics Participating in 4th International mRNA Health Conference
DURHAM, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company is participating
View HTML

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

Tweets